Lipocine Inc. Files 8-K Report

Ticker: LPCN · Form: 8-K · Filed: Jun 23, 2025 · CIK: 1535955

Lipocine Inc. 8-K Filing Summary
FieldDetail
CompanyLipocine Inc. (LPCN)
Form Type8-K
Filed DateJun 23, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

TL;DR

Lipocine filed a routine 8-K on 6/23/25. No major news, just compliance.

AI Summary

Lipocine Inc. filed an 8-K on June 23, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 30, 2011, is incorporated in Delaware and headquartered in Salt Lake City, Utah. This filing does not appear to contain specific material events or financial figures beyond standard reporting requirements.

Why It Matters

This 8-K filing indicates Lipocine Inc. is fulfilling its regulatory reporting obligations. Investors should review the full filing for any specific material events or financial updates that may impact the company's stock.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no indication of significant new risks or material adverse information.

Key Players & Entities

  • Lipocine Inc. (company) — Registrant
  • Marathon Bar Corp (company) — Former company name
  • June 23, 2025 (date) — Date of earliest event reported
  • November 30, 2011 (date) — Date of name change
  • Delaware (jurisdiction) — State of incorporation
  • Salt Lake City, Utah (location) — Address of principal executive offices

FAQ

What is the primary purpose of this 8-K filing for Lipocine Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 23, 2025.

When was Lipocine Inc. previously known by another name?

Lipocine Inc. was formerly known as Marathon Bar Corp, with the date of name change being November 30, 2011.

In which state is Lipocine Inc. incorporated?

Lipocine Inc. is incorporated in Delaware.

What is the principal executive office address for Lipocine Inc.?

The principal executive office address for Lipocine Inc. is 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is the Commission File Number for Lipocine Inc.'s SEC filings?

The Commission File Number for Lipocine Inc. is 001-36357.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding Lipocine Inc. (LPCN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.